In my first post on this blog, I set myself 3 PhD-related goals for 2017. One of those goals was to read more widely, and more frequently, and I decided that doing the #365papers challenge would be a good way to do that.

Here’s my March update. I found this month reallt difficult to be honest, I was super busy with other things at work and didn’t feel like reading when I had a to do list longer than my arm. I missed a few days in a row and towards the end of the month when I had 10 papers to catch up on, I was making excuses and looking for ways to wriggle out of the challenge. I didn’t though – hoorah! I made time to read and now I’m all caught up.

March’s reading:

1. Promoting recruitment using information management efficiently (PRIME): study protocol for a stepped-wedge cluster randomised controlled trial within the Restart or Stop Antithrombotics Randomised Trial (RESTART)
2. A little more conversation please? Qualitative study of researchers’ and patients’ interview account of training for patient and public involvement in clinical trials
3. Are there fundamental deficiencies in megatrial methodology?
4. Managing clinical trials
5. From protocol to published report: a study of consistency in the reporting of academic drug trials
6. Understanding controlled trials: why are randomised controlled trials so important?
7. Understanding controlled trials: baseline imbalance in randomised controlled trials
8. Understanding controlled trials: randomising groups of patients
9. Using marketing theory to inform strategies for recruitment: a recruitment optimisation model and the txt2stop experience
10. The natural history of conducting and reporting clinical trials: interviews with trialists
11. Understanding controlled trials: what is a patient preference trial?
12. Strategies for increasing recruitment to randomised controlled trials: systematic review
13. Why clinical trial outcomes fail to translate into benefits for patients
14. Blog – How marketing is undermining clinical trials
15. Marketing trials, marketing tricks – how to spot them and how to stop them
16. The changing face of clinical trials: pragmatic trials
17. Equipoise across the patient population: optimising recruitment to a randomised controlled trial
18. Why prudence is needed when interpreting articles reporting clinical trial results in mental health
19. The possibility of critical realist randomised controlled trials
20. The association of funding source on effect size in randomised controlled trials: 2013-2016 – a cross-sectional survey and meta-analysis
21. Improving the recruitment activity of clinicians in randomised controlled trials: a systematic review
22. Registry-based pragmatic trials in heart failure: current experience and future directions
23. Barriers to recruitment in pediatric obesity trials: comparing opt-in an dopt-out recruitment approaches
24. Sharing raw data from clinical trials: what progress since we first asked “Whose data set is it anyway?”
25. Pharmafile Opinion – Are we prepared for the ‘real world’?
26. Experience with direct-to-patient recruitment for enrollment into a clinical trial in a rare disease: a web-based study
27. Financial Times article – Small patient groups hinder progress of clinical trials
28. Fast Company, 3 Minute Read – This compay is helping patients get paid for their influence
29. Recruitment of minority adolescents and young adults into randomised clinical trials: testing the design of the technology enhanced community health nursing (Tech-N) pelvic inflammatory disease trial
30. When clinical trials compete: prioritizing study recruitment
31. The continuing unethical conduct of underpowered clinical trials

If you have any recommended reads that are related to clinical trials/methodology/health services research and that kind of thing, I’d welcome them!